Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03660046 · ClinicalTrials.gov registry record
Contraceptive Hormones, Immunity, and Microbiome Evaluation
A clinical trial, sponsored by Emory University.
- Completed
- Registry status
- 155
- Enrollment target
NCT03660046 is a clinical trial that has completed, run by Emory University. The registered enrollment target is 155 participants.
The verdict
NCT03660046 has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- 155 participants
- Enrollment target
Study Summary
The study is a prospective cohort study to explore the mechanisms underlying the HIV risk associated with pharmacologic doses of exogenous sex hormones via hormonal contraceptives specially progestin-containing hormonal contraception (HC). The study seeks to test that HC induce immunologic changes capable of altering HIV susceptibilities, that these effects will vary by contraceptive type, and that they will be modified by the vaginal microenvironment.
Interventions
- DRUG Depot medroxyprogesterone acetate (DMPA)
- DRUG Etonogestrel implant (Eng-Implant)
- DRUG Levonorgestrel IUD (Lng-IUD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2018-12-07 |
| Est. Completion | 2023-09-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03660046
The ClinicalTrials.gov registry entry for NCT03660046 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Depot medroxyprogesterone acetate (DMPA) is the first listed.
NCT03660046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03660046 about?
NCT03660046 is a clinical study titled "Contraceptive Hormones, Immunity, and Microbiome Evaluation". The study is a prospective cohort study to explore the mechanisms underlying the HIV risk associated with pharmacologic doses of exogenous sex hormones via hormonal contraceptives specially progestin-containing hormonal contraception (HC). The study seeks to test that HC induce immunologic changes c...
What is the current status of trial NCT03660046?
This trial is currently completed. The enrollment target is 155 participants. The study started on 2018-12-07. Estimated completion is 2023-09-07.
What interventions are being tested in trial NCT03660046?
The interventions under investigation include: Depot medroxyprogesterone acetate (DMPA) (DRUG), Etonogestrel implant (Eng-Implant) (DRUG), Levonorgestrel IUD (Lng-IUD) (DRUG).
Who is sponsoring clinical trial NCT03660046?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.